

*Unless defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 25 June 2015 (the “Prospectus”) issued by PuraPharm Corporation Limited (the “Company”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares being offered.*

*This announcement is not an offer of securities for sale in the United States. The Company has not registered and does not intend to register any securities referred to in this announcement under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). Securities of the Company may not be offered or sold in the United States absent registration under the U.S. Securities Act or an applicable exemption from the registration requirements under the U.S. Securities Act. There will not be and is not currently intended to be any public offering of securities in the United States.*



**PuraPharm**  
**PuraPharm Corporation Limited**  
**培力控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1498)**

**STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND  
LAPSE OF OVER-ALLOTMENT OPTION**

The Company announces that the stabilization period in connection with the Global Offering ended on 30 July 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by BOCOM International Securities Limited, the Stabilizing Manager, during the stabilization period were:

- (1) over-allocations of an aggregate of 10,669,500 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and

(2) the successive purchases of an aggregate of 10,669,500 Shares in the price range of HK\$3.70 to HK\$5.87 per Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last on-market purchase made by the Stabilizing Manager during the stabilization period was on 15 July 2015 at the price of HK\$5.62 per Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%).

The Over-allotment Option has not been exercised by the Sole Global Coordinator (on behalf of the International Underwriters) during the stabilization period and has lapsed on 30 July 2015.

## **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

The Company makes this announcement pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) and announces that the stabilization period in connection with the Global Offering ended on 30 July 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by BOCOM International Securities Limited, the Stabilizing Manager during the stabilization period were:

- (1) over-allocations of an aggregate of 10,669,500 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and
- (2) the successive purchases of an aggregate of 10,669,500 Shares in the price range of HK\$3.70 to HK\$5.87 per Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last on-market purchase made by the Stabilizing Manager during the stabilization period was on 15 July 2015 at the price of HK\$5.62 per Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%).

## **LAPSE OF THE OVER-ALLOTMENT OPTION**

The Company further announces that the Over-allotment Option has not been exercised by the Sole Global Coordinator (on behalf of the International Underwriters) during the stabilization period and has lapsed on 30 July 2015.

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 30 July 2015

*As at the date of this announcement, the executive Directors are Chan Yu Ling, Abraham, Tsoi Kam Biu, Alvin, Leung Chin Man and Man Yee Wai, Viola; the non-executive Director is Chan Kin Man, Eddie; and the independent non-executive Directors are Leung Lim Kin, Simon, Chan Kin Keung, Eugene, Ho Kwok Wah, George and Tsui Lap Chee.*